CAS 164650-44-6|Efinaconazole

Introduction：Basic information about CAS 164650-44-6|Efinaconazole, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Efinaconazole BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Efinaconazole
CAS Number	164650-44-6	Molecular Weight	348.390
Density	1.3±0.1 g/cm3	Boiling Point	512.2±60.0 °C at 760 mmHg
Molecular Formula	C₁₈H₂₂F₂N₄O	Melting Point	/
MSDS	/	Flash Point	263.6±32.9 °C

Names

Name	efinaconazole
Synonym	More Synonyms

Efinaconazole BiologicalActivity

Description	Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis.IC50 value: 0.0039 ug/ml (MIC for T. mentagrophytes SM-110) [1]Target: antifungal agentin vitro: Efinaconazole was 4-fold more active than itraconazole against T. mentagrophytes SM-110 (MICs of 0.0039 and 0.016 μg/ml, respectively). Similarly, efinaconazole was 8-fold more active than clotrimazole against C. albicans ATCC 10231 (MICs of 0.00098 and 0.0078 μg/ml, respectively) [1]. In a comprehensive survey of 1,493 isolates, efinaconazole MICs against T. rubrum and T. mentagrophytes ranged from ≤ 0.002 to 0.06 μg/ml, with 90% of isolates inhibited (MIC90) at 0.008 and 0.015 μg/ml, respectively. Efinaconazole MICs against 105 C. albicans isolates ranged from ≤ 0.0005 to >0.25 μg/ml, with 50% of isolates inhibited (MIC50) by 0.001 and 0.004 μg/ml at 24 and 48 h, respectively [2].in vivo: The therapeutic efficacy of KP-103, a triazole derivative, for 10 guinea pigs with interdigital tinea pedis or tinea corporis was investigated. Topical KP-103 solution (0.25 to 1%) was dose-dependently effective in treating both dermatophytoses. A 1% KP-103-treatment rendered all infected skins culture-negative on day-2 posttreatment [3].
Related Catalog	Signaling Pathways >>Anti-infection >>FungalResearch Areas >>Infection
References	[1]. Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57(5):2405-9. [2]. Jo Siu WJ, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013 Apr;57(4):1610-6. [3]. Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46(7):425-32.

Description

Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis.IC50 value: 0.0039 ug/ml (MIC for T. mentagrophytes SM-110) [1]Target: antifungal agentin vitro: Efinaconazole was 4-fold more active than itraconazole against T. mentagrophytes SM-110 (MICs of 0.0039 and 0.016 μg/ml, respectively). Similarly, efinaconazole was 8-fold more active than clotrimazole against C. albicans ATCC 10231 (MICs of 0.00098 and 0.0078 μg/ml, respectively) [1]. In a comprehensive survey of 1,493 isolates, efinaconazole MICs against T. rubrum and T. mentagrophytes ranged from ≤ 0.002 to 0.06 μg/ml, with 90% of isolates inhibited (MIC90) at 0.008 and 0.015 μg/ml, respectively. Efinaconazole MICs against 105 C. albicans isolates ranged from ≤ 0.0005 to >0.25 μg/ml, with 50% of isolates inhibited (MIC50) by 0.001 and 0.004 μg/ml at 24 and 48 h, respectively [2].in vivo: The therapeutic efficacy of KP-103, a triazole derivative, for 10 guinea pigs with interdigital tinea pedis or tinea corporis was investigated. Topical KP-103 solution (0.25 to 1%) was dose-dependently effective in treating both dermatophytoses. A 1% KP-103-treatment rendered all infected skins culture-negative on day-2 posttreatment [3].

Related Catalog

Signaling Pathways >>Anti-infection >>FungalResearch Areas >>Infection

References

[1]. Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57(5):2405-9.

[2]. Jo Siu WJ, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013 Apr;57(4):1610-6.

[3]. Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46(7):425-32.

Chemical & Physical Properties

Density	1.3±0.1 g/cm3
Boiling Point	512.2±60.0 °C at 760 mmHg
Molecular Formula	C₁₈H₂₂F₂N₄O
Molecular Weight	348.390
Flash Point	263.6±32.9 °C
Exact Mass	348.176178
PSA	54.18000
LogP	3.46
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.590
InChIKey	NFEZZTICAUWDHU-RDTXWAMCSA-N
SMILES	C=C1CCN(C(C)C(O)(Cn2cncn2)c2ccc(F)cc2F)CC1
Storage condition	2~8℃

Safety Information

Hazard Codes	Xi

Synonyms

Efinaconazole [USAN:INN]

(2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol

UNII-J82SB7FXWB

KP-103

(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol

Efinaconazole (JAN/USAN/INN)

Efinaconazole

1-Piperidineethanol, α-(2,4-difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βR)-

Jublia

Efinaconazole [INN]

Recommended......